相似文献
1
Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.前列腺癌靶向 N-(2-羟丙基)甲基丙烯酰胺共聚物/多西他赛缀合物。
Macromol Biosci. 2012 Mar;12(3):412-22. doi: 10.1002/mabi.201100340.
2
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.间隔长度会影响靶向结合多西他赛的前列腺特异性膜抗原表达前列腺癌的疗效。
J Drug Target. 2013 Dec;21(10):968-80. doi: 10.3109/1061186X.2013.833207.
3
Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.HPMA 共聚物-RGDfK 缀合物对前列腺癌治疗的主动和被动靶向紫杉醇的比较。
Mol Pharm. 2011 Aug 1;8(4):1090-9. doi: 10.1021/mp100402n. Epub 2011 Jun 1.
4
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.一种与澳瑞他汀偶联的、针对前列腺特异性膜抗原的全人源单克隆抗体具有强大的抗肿瘤活性。
Clin Cancer Res. 2006 Apr 15;12(8):2591-6. doi: 10.1158/1078-0432.CCR-05-2107.
5
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.一种抗体药物偶联物PSMA-ADC在患者来源的前列腺癌异种移植模型中的疗效研究。
Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.
6
HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.基于 HPMA 共聚物的联合治疗对前列腺癌干细胞/祖细胞和分化细胞均有毒性，可诱导持久的抗肿瘤效果。
J Control Release. 2013 Dec 28;172(3):946-53. doi: 10.1016/j.jconrel.2013.09.005. Epub 2013 Sep 14.
7
Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.用于前列腺癌药物递送的 HPMA 共聚物-氨基己基格尔德霉素-RGDfK 缀合物的生物分布。
Mol Pharm. 2009 Nov-Dec;6(6):1836-47. doi: 10.1021/mp900134c.
8
[Biodistribution of N-(2-hydroxypropyl) methacrylamide copolymer-bound mitoxantrone in mice bearing Ehrlich solid tumor].[携带艾氏实体瘤小鼠中N-(2-羟丙基)甲基丙烯酰胺共聚物结合米托蒽醌的生物分布]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004 Dec;21(6):930-4.
9
The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.聚合物载体的结构控制了载有阿霉素和多西他赛的 HPMA 共聚物缀合物联合治疗肿瘤的实验组合治疗的疗效。
J Control Release. 2017 Jan 28;246:1-11. doi: 10.1016/j.jconrel.2016.12.004. Epub 2016 Dec 6.
10
Targeting tumor angiogenic vasculature using polymer-RGD conjugates.使用聚合物-RGD 偶联物靶向肿瘤血管生成脉管系统。
J Control Release. 2005 Jan 20;102(1):191-201. doi: 10.1016/j.jconrel.2004.09.023.
引用本文的文献
1
A Nanostrategy for Efficient Imaging-Guided Antitumor Therapy through a Stimuli-Responsive Branched Polymeric Prodrug.一种通过刺激响应性支化聚合物前药实现高效成像引导抗肿瘤治疗的纳米策略。
Adv Sci (Weinh). 2020 Jan 31;7(6):1903243. doi: 10.1002/advs.201903243. eCollection 2020 Mar.
2
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.间隔长度会影响靶向结合多西他赛的前列腺特异性膜抗原表达前列腺癌的疗效。
J Drug Target. 2013 Dec;21(10):968-80. doi: 10.3109/1061186X.2013.833207.
3
HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.基于 HPMA 共聚物的联合治疗对前列腺癌干细胞/祖细胞和分化细胞均有毒性，可诱导持久的抗肿瘤效果。
J Control Release. 2013 Dec 28;172(3):946-53. doi: 10.1016/j.jconrel.2013.09.005. Epub 2013 Sep 14.
本文引用的文献
1
2
Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen.前列腺特异性膜抗原7E11-C5.3表位的生化特性鉴定与定位
Urol Oncol. 1995 Jan-Feb;1(1):29-37. doi: 10.1016/1078-1439(95)00004-2.
3
Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.抗前列腺特异性膜抗原单链免疫毒素对前列腺癌的临床前评价。
J Immunother. 2010 Apr;33(3):262-71. doi: 10.1097/CJI.0b013e3181c5495c.
4
Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.通过 EPR 效应实现大分子药物的肿瘤选择性递送：背景与未来展望。
Bioconjug Chem. 2010 May 19;21(5):797-802. doi: 10.1021/bc100070g.
5
Docetaxel-based combination therapy for castration-resistant prostate cancer.多西他赛为基础的联合治疗用于去势抵抗性前列腺癌。
Ann Oncol. 2010 Nov;21(11):2135-2144. doi: 10.1093/annonc/mdq050. Epub 2010 Mar 29.
6
Molecular and traditional chemotherapy: a united front against prostate cancer.分子和传统化疗：联合对抗前列腺癌。
Cancer Lett. 2010 Jul 1;293(1):1-14. doi: 10.1016/j.canlet.2009.11.019. Epub 2010 Feb 1.
7
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.针对前列腺特异性膜抗原的单克隆抗体（3C6）的临床前评估
Curr Radiopharm. 2009 Jan;2(1):9-17. doi: 10.2174/1874471010902010009.
8
Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.HPMA 共聚物缀合物是否有作为临床有用的纳米药物的未来？对当前现状和未来机遇的批判性综述。
Adv Drug Deliv Rev. 2010 Feb 17;62(2):272-82. doi: 10.1016/j.addr.2009.12.005. Epub 2009 Dec 11.
9
Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.利用 HPMA 共聚物纳米药物制剂提高联合抗癌疗法的疗效。
Adv Drug Deliv Rev. 2010 Feb 17;62(2):203-30. doi: 10.1016/j.addr.2009.11.028. Epub 2009 Dec 4.
10
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.三种针对不同 PSMA 表位的构象抗体是前列腺癌有前途的诊断和治疗工具。
Prostate. 2010 Apr 1;70(5):562-9. doi: 10.1002/pros.21090.
Zotero 插件